RCKT Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (RCKT) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.41 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.2% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States.
Sector
Healthcare
Industry
Biotechnology